Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...

While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including ...

Hims & Hers Health (HIMS) stock is getting attention from options bulls after beating first-quarter expectations ...

Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 20 cents in first-quarter 2025 compared with the ...

Key Takeaways Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled.However, the health and ...